SCHEMBL31023451

SCHEMBL31023451

O=C(NCc1ccc(-c2ccccc2)cc1)c1cn[nH]c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.62
NR1H4 Q96RI1 2/20 0.62
HDAC3 O15379 1/20 0.61
HDAC4 P56524 1/20 0.61
HDAC1 Q13547 1/20 0.61
HDAC7 Q8WUI4 1/20 0.61
HDAC2 Q92769 1/20 0.61
HDAC10 Q969S8 1/20 0.61
HDAC11 Q96DB2 1/20 0.61
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
HDAC9 Q9UKV0 1/20 0.61
HDAC5 Q9UQL6 1/20 0.61
MMP13 P45452 1/20 0.59
NPC1 O15118 1/20 0.59
RAB9A P51151 1/20 0.59
ROCK2 O75116 6/20 0.57
HPGDS O60760 2/20 0.57
MME P08473 1/20 0.57
TRPV1 Q8NER1 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4879445 0.91 ROCK2 (0.60) HDAC2HDAC8HDAC6RAB9AROCK2
SCHEMBL18741074 0.82 L3MBTL1 (0.61) EPHX2ROCK2ROCK1SMN1; SMN2
SCHEMBL30739187 0.79 KLKB1 (0.54) ROCK2ROCK1
SCHEMBL4882240 0.79 MAPK14 (0.59) EPHX2NR1H4HDAC3HDAC1HDAC2
SCHEMBL539059 0.78 EPHX2 (0.84) EPHX2NR1H4HDAC3HDAC4HDAC1
SCHEMBL31023536 0.77 HPGDS (0.69) EPHX2NR1H4HDAC3HDAC4HDAC1
SCHEMBL15873800 0.77 L3MBTL1 (0.58) EPHX2NR1H4HDAC1HDAC6NPC1
SCHEMBL4885892 0.77 ROCK2 (0.62) HDAC3HDAC4HDAC1HDAC7HDAC2
Biphenyl SCHEMBL27717173 0.76 AKT1 (0.59) ROCK2MMEROCK1AKT1EGFR
SCHEMBL3018586 0.76 HTT (0.49) ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027096-A1 PHD INHIBITORS UNIV OXFORD INNOVATION LTD (GB) 2026-01-29 US disclosed
EP-4655288-A1 PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 EP disclosed
EP-4655294-A1 PYRAZOLE DERIVSTIVES AS PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 EP disclosed
WO-2024157019-A1 PHD INHIBITORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-08-02 WO disclosed
WO-2024157014-A1 PYRAZOLE DERIVSTIVES AS PHD INHIBITORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027096-A1 PHD INHIBITORS HIF1AN, HIF1A, EGLN1 EPHX2 1495/4885NR1H4 4293/4885HDAC3 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.